Pharmacy Drugs
Recent Posts
- Malignant Brain Tumors: Chemotherapy Alone Is Just As Effective As Radiation / New Positive Prognostic Factor Found
- Positive Interim Data From Minnow Medical Peripheral Artery Disease Trial Presented At TCT 2009 Conference
- Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint In A Phase II Clinical Trial In Type 2 Diabetic Patients
- Largest Clinical Trial To Test Benefits Of Aspirin In Australia
- University Of Florida To Receive $29.5 Million In Recovery Act Funds To Begin Study Of Whether Exercise Prevents Disability In Older Adults
Random Posts
- Zydena Is Efficacious In Once Daily Dosing For Erectile Dysfunction/Positive BPH Results
- Addex ADX10059 Monotherapy Is Effective On GERD Symptoms In Phase IIb Clinical Trial
- Young Adults Who Exercise Get Higher IQ
- CombinatoRx'S Synavive (CRx-102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension Trial
- Heart Transplant Recipients Can Improve Fitness And Perform High Intensity Workouts
- Pharmacy Organisations Back H1N1 Swine Flu Vaccine
- New Anti-Rejection Drug Effective And More Affordable
- ERYtech Pharma Starts Its Pivotal Clinical Trial For GRASPA(R) In Acute Lymphoblastic Leukaemia
- National Effort To Recruit Volunteers For Medical Research
- Azaya Therapeutics Receives FDA Authorization To Start Phase I Cancer Trial
FDA Accepts Arno Therapeutics’ IND For AR-12 A PDK1 Inhibitor That Blocks The PI3K/Akt Pathway
Posted by: admin in Pharmacy Drugs on November 23rd, 2009
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, announced that the U.S.